Opening soonPhase 4Interventional
What this study is about
To compare the efficacy and safety of sacubitril/Allisartan versus amlodipine in the antihypertensive treatment of overweight/obese patients with primary hypertension
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 75 Years
SexAll
Healthy volunteersNot accepted
ConditionHypertension
Full registry criteria
Inclusion Criteria: 1. Aged between 18 and 75 years inclusive, regardless of gender; 2. Body Mass Index (BMI) ≥ 24 kg/m²; 3. Diagnosed with essential hypertension, either untreated or currently receiving antihypertensive medication; 4. For patients who have not received antihypertensive medication in the past 3 months, the msSBP at the screening visit must be ≥ 150 mmHg and \< 180 mmHg; 5. For patients currently receiving antihypertensive medication, the msSBP at the screening visit must be ≥ 140 mmHg and \< 180 mmHg; and at the visit after the washout period, the msSBP must be ≥ 150 mmHg and \< 180 mmHg. Exclusion Criteria: 1. Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, etc.; 2. History of or diagnostic evidence for obstructive sleep apnea (OSA); 3. History of angioedema; 4. History of or diagnostic evidence for secondary hypertension; 5. Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, or stroke occurring within 12 months; New York Heart Association (NYHA) Class II-IV heart failure, large aortic aneurysm or aortic dissection, atrioventricular block of degree II or higher, sick sinus syndrome, bradycardia (heart rate \< 50 beats per minute) or other arrhythmias requiring antiarrhythmic drugs, as well as severe diseases such as epilepsy and syncope; 6. Clinically significant abnormalities in laboratory tests (serum potassium \> 5.5 mmol/L or \< 3.5 mmol/L; serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2.5 × upper limit of normal (ULN); serum creatinine \> 1.5 × ULN); 7. Type 1 diabetes mellitus and type 2 diabetes mellitus with poor glycemic control (glycated hemoglobin (HbA1c) \> 8.0%); 8. Patients currently using drugs with weight-loss effects such as glucagon-like peptide-1 (GLP-1) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors; 9. Patients undergoing hemodialysis or strict salt-restriction therapy; 10. Known or suspected allergy to sacubitril/allisartan, sacubitril/valsartan sodium, amlodipine, or related drugs; 11. Patients deemed unsuitable for participation in the study by the investigator.
Treatments and study arms
sacubitril/allisartan
Drug
Oral administration of sacubitril/allisartan 240mg once daily for 4 consecutive weeks. If blood pressure reaches the target, the original regimen is continued; otherwise, the dose of sacubitril/valsartan is increased to 480mg once daily for another 4 weeks of treatment
Amlodipine
Drug
Amlodipine group: Oral administration of amlodipine 5mg once daily for 4 consecutive weeks. If blood pressure reaches the target, the original regimen is continued; otherwise, the dose of amlodipine is increased to 10mg once daily for another 4 weeks of treatment
Primary outcomes
The change in the mean sitting systolic blood pressure (msSBP) from baseline to week 8, assessed for sacubitril/allisartan as compared to amlodipineFrom the start of randomization to the end of treatment at 8 weeks
